Dual Cytokine Antibody Fusion Proteins
Download Dual Cytokine Antibody Fusion Proteins full books in PDF, epub, and Kindle. Read online free Dual Cytokine Antibody Fusion Proteins ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Stefan R. Schmidt |
| Publisher | : John Wiley & Sons |
| Total Pages | : 995 |
| Release | : 2013-01-28 |
| Genre | : Medical |
| ISBN | : 1118354583 |
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.
| Author | : Klas Kärre |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 250 |
| Release | : 2012-12-06 |
| Genre | : Medical |
| ISBN | : 3642468594 |
Our understanding of the function of natural killer (NK) cells has dramatically changed in recent years. The discovery of NK receptors specific for MHC class I molecules, and the study of the role of co-stimulatory and adhesion molecules have led to an understanding of how NK cells recognize tumor and virally infected cells that have lost expression of MHC class I molecules or have altered distribution of normal cell surface molecules. Such recognition events lead to intracellular signals which can be either stimulatory or inhibitory. This book provides an insight into how NK cells develop, how they learn to distinguish altered cells from normal cells, and into their biological role in controlling infections and tumors.
| Author | : Brian A. Baldo |
| Publisher | : Springer |
| Total Pages | : 623 |
| Release | : 2016-08-12 |
| Genre | : Medical |
| ISBN | : 3319304720 |
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.
| Author | : Steven M. Chamow |
| Publisher | : Wiley-Liss |
| Total Pages | : 312 |
| Release | : 1999-04-13 |
| Genre | : Science |
| ISBN | : 9780471183587 |
Thoroughly detailed and illustrated, this book examines the construction, properties, applications, and problems associated with specific types of fusion molecules used in clinical and research medicine. The editors present an overview of the field, followed by nine chapters divided into two general sections based on the two primary parts of the antibody molecule: Fab fusion proteins and Fc fusion proteins. In addition, numerous renowned scientists in the field have contributed outlines demonstrating man-made molecules that will be required not only to overcome the limitations of monoclonal antibodies, but also to extend the principle of selective targeting. Divided into specific, accessible sections, Antibody Fusion Proteins includes: * Chapters describing Fc fusion proteins, as well as several classes of antigen-binding proteins * Complete details on the design and molecular construction of genetically engineered fusion molecules * Useful information on molecular purification, large-scale production, practical applications, and their therapeutic potential * The latest data on forming fusion proteins with toxins, cytokines, or enzymes that can activate a prodrug
| Author | : John C. Marshall |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 458 |
| Release | : 2002-01-21 |
| Genre | : Medical |
| ISBN | : 9783540425892 |
This book brings together basic scientists or clinicians from a variety of different backgrounds - immunology, infectious diseases or critical care - who share a common interest in understanding the changes that occur in immune responses in sepsis. It provides an up-to-date and unrivalled synthesis of current research in this rapidly developing field.
| Author | : Steven M. Chamow |
| Publisher | : John Wiley & Sons |
| Total Pages | : 345 |
| Release | : 2013-12-18 |
| Genre | : Science |
| ISBN | : 3527675280 |
Edited by three pioneers in the field, each with longstanding experience in the biotech industry, and a skilled scientific writer, this is the first book to cover every step in the development and production of immunoglobulin Fc-fusion proteins as therapeutics for human disease: from choosing the right molecular design, to pre-clinical characterization of the purified product, through to batch optimization and quality control for large-scale cGMP production. The whole of the second part is devoted to case studies of Fc-fusion proteins that are now commercially successful products. In this section, the authors, several of whom were personally involved in clinical development of the products themselves, detail the product?s background and give insight into issues that were faced and how these issues were overcome during clinical development. This section also includes a chapter on promising new developments for the future. An invaluable resource for professionals already working on Fc-fusion proteins and an excellent and thorough introduction for physicians, researchers, and students entering the field.
| Author | : Brian H. Santich |
| Publisher | : Frontiers Media SA |
| Total Pages | : 97 |
| Release | : 2021-01-21 |
| Genre | : Medical |
| ISBN | : 2889664155 |
CK is affiliated with the Roche Innovation Center Zurich, holds stocks and has patents with Hoffmann-La Roche company. NKC reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest/equity/options in Y-Mabs Therapeutics Inc., and in Abpro-Labs, and owning stock options in Eureka Therapeutics. NKC is the inventor of pending and issued patents filed by MSK, including hu3F8 and 8H9 licensed to Ymabs Therapeutics, beta-glucan to Biotec Pharmacon, and HER2 bispecific antibody to Abpro-labs. NKC is an advisory board member for Abpro-Labs and Eureka Therapeutics
| Author | : |
| Publisher | : |
| Total Pages | : 0 |
| Release | : 2002 |
| Genre | : Cells |
| ISBN | : 9780815332183 |
| Author | : Anand Rotte |
| Publisher | : Springer |
| Total Pages | : 434 |
| Release | : 2016-12-19 |
| Genre | : Medical |
| ISBN | : 3319480669 |
This book focusses on the different types of immunotherapeutics that are currently being used and developed for the treatment of melanoma. In recent years, immunotherapy has revolutionized the treatment of metastatic melanoma and other types of cancer. Discussing treatment options for melanoma and the success of immunotherapy along with the challenges of immunotherapy, this book covers epidemiology, susceptibility genes, and treatment recommendations from Society for Immunotherapy of Cancer, as well as immune based therapies such as aldesleukin, Intron-A, Sylatron, Yervoy, Opdivo, Keytruda, Imlygic, DC vaccines and adoptive cell therapy. The detailed information included on the key immune cells involved in anti-tumor immune response and immune-inhibitory mechanisms in tumor microenvironment will aid the understanding of tumor immunology. Both academic as well as industry-based researchers, developing novel anti-cancer therapies, will also benefit from the details of promising molecular targets and immunotherapeutic strategies under investigation. With 132 illustrations including synopsis tables for important information, over 1200 references (majority of which are openly accessible) and details of more than 150 ongoing clinical trials, this book is a valuable source of information for health care providers as well as cancer biologists interested in learning about melanoma and the significant advances made by immunotherapy.
| Author | : Michael J. Parnham |
| Publisher | : Springer Nature |
| Total Pages | : 888 |
| Release | : 2019-12-10 |
| Genre | : Medical |
| ISBN | : 3030108112 |
Principles of Immunopharmacology provides a unique source of essential knowledge on the immune response, its diagnosis and its modification by drugs and chemicals. The 4th edition of this internationally recognized textbook has been revised to include recent developments, but continues the established format, dealing with four related fields in a single volume, thus obviating the need to refer to several different textbooks. The first section of the book, providing a basic introduction to immunology and its relevance for human disease, has been updated to accommodate new immunological concepts, particularly the role of epigenetics and the latest understanding of cancer immunology. The second section on immunodiagnostics offers a topical description of widely used molecular techniques and a new chapter on imaging techniques. This is followed by a systematic coverage of drugs affecting the immune system, including natural products. This third section contains 15 updated chapters, covering classical immunopharmacological topics such as anti-asthmatic, anti-rheumatic and immunosuppressive drugs, but also deals with antibiotics, plant-derived and dietary agents, with new chapters on monoclonal antibodies, immunotherapy in sepsis and infection, drugs for soft-tissue autoimmunity and cell therapy. The book concludes with a chapter on immunotoxicology and drug safety tests. Aids to the reader include a two-column format, glossaries of technical terms and appendix reference tables. The emphasis on illustrations is maintained from the first three editions. The book is a valuable single reference for undergraduate and graduate medical and biomedical students, postgraduate chemistry and pharmacy students, researchers in chemistry, biochemistry and the pharmaceutical industry and researchers lacking basic immunological knowledge, who want to understand the actions of drugs on the immune system.
